1. Presumed cancer‐associated retinopathy (CAR) mimicking Sudden Acquired Retinal Degeneration Syndrome (SARDS) in canines
- Author
-
Tatjana Lazic, Kabhilan Mohan, Grazyna Adamus, Sinisa D. Grozdanic, Markus H. Kuehn, and Helga Kecova
- Subjects
Male ,retina ,medicine.medical_specialty ,genetic structures ,Fundus Oculi ,040301 veterinary sciences ,Retinitis ,Diagnosis, Differential ,0403 veterinary science ,03 medical and health sciences ,Dogs ,0302 clinical medicine ,Ophthalmology ,retinopathy ,Electroretinography ,cancer ,Animals ,Medicine ,Dog Diseases ,Autoantibodies ,Proteinuria ,General Veterinary ,medicine.diagnostic_test ,Paraneoplastic Syndromes, Ocular ,business.industry ,Retinal Degeneration ,Cancer ,Histology ,Original Articles ,04 agricultural and veterinary sciences ,medicine.disease ,immunity ,SARDS ,030221 ophthalmology & optometry ,Original Article ,Female ,Sudden acquired retinal degeneration ,sense organs ,Sarcoma ,medicine.symptom ,business ,microarray ,Retinopathy - Abstract
Objective To describe functional and structural features of presumed cancer‐associated retinopathy (CAR) mimicking sudden acquired retinal degeneration syndrome (SARDS) in dogs and describe treatment outcomes. Animals Subjects were 17 dogs from 8 eight US states and Canada diagnosed with SARDS or immune‐mediated retinitis (IMR) by 12 ophthalmologists. Nine eyes from seven deceased patients were used for microarray (MA), histology, or immunohistochemical (IHC) analysis. Procedures Dogs underwent complete ophthalmic examination, including retinal photography, optical coherence tomography (OCT), chromatic pupil light reflex testing (cPLR), and electroretinography (ERG), in addition to complete systemic examination. Histology, microarray, and IHC analysis were performed in CAR retinas to evaluate histological and molecular changes in retinal tissue. Results None of the patients evaluated satisfied previously established criteria for diagnosis of SARDS (flat ERG+ no red – good blue PLR), and all were diagnosed with IMR. All patients were diagnosed with a cancer: meningioma (24%), sarcoma (18%), pituitary tumor (12%), and squamous cell carcinoma (12%), other (34%). Median survival time was 6 months from diagnosis (range 1‐36 months). Most frequent systemic abnormalities were as follows: proteinuria (78%); elevated liver enzymes (47%); and metabolic changes (PU/PD, polyphagia – 24%). Immunosuppressive therapy resulted in the reversal of blindness in 44% of treated patients, with 61% of all treated patients recovering and/or maintaining vision. Median time for preservation of vision was 5 months (range 1‐35 months). Conclusions Observed changes are highly suggestive of immune‐mediated damage in IMR‐CAR eyes. A relatively high percentage of patients with CAR responded positively to immunosuppressive therapy.
- Published
- 2020
- Full Text
- View/download PDF